Clinical Trial Update: Low-Dose Ibuprofen in Improving Cognitive Impairment in Patients With Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating low-dose ibuprofen for cognitive impairment in cancer patients has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Impairment
• Malignant Neoplasm

Drugs mentioned

• Ibuprofen (IBUPROFEN)

Snippet

Sponsor: University of Rochester NCORP Research Base | Conditions: Cognitive Impairment, Malignant Neoplasm | Phase 2 | Status: COMPLETED | Results posted: 2023-04-21